![]() |
市場調查報告書
商品編碼
1454860
人工水晶體的全球市場(2024年):2023年~2029年的分析2024 IOL Market Report: Global Analysis for 2023 to 2029 |
本報告提供全球人工水晶體市場相關調查,提供市場概要,以及今後5年的市場效能預測,重要的未來趨勢,及加入此市場的主要34企業的企業簡介等資訊。
The "2024 IOL Market Report" provides a new, extensive historical analysis of the market, recapping key events and market trends from the previous year and examining 2017-to-2023 sales by region for monofocal, presbyopia-correcting, toric, and other IOLs. This analysis also provides a view of 2023 sales for monofocal and premium IOLs by company tier.
The report reviews and analyzes the large number of EDOF and trifocal IOLs that were launched in Q4-2023. It also features survey data showing how the increasing popularity of monofocal plus IOLs is slowing the adoption of PC-IOLs.
In addition, the new report examines the challenges and opportunities created by the wave of the post-LVC cataract patients that is making IOL selection and surgery more challenging.
The "2024 IOL Market Report" provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 11 categories of IOLs: commodity monofocal, enhanced monofocal/intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, postoperatively adjustable, and phakic IOLs. Additionally, 34 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
The "2024 IOL Market Report" offers a comprehensive look at the global IOL market, with eight regional/economic breakouts. The following information is included in this report:
Bill Freeman has more than 35 years of experience developing, manufacturing, and marketing cataract surgery products. He has held key executive positions at four firms that produce ophthalmic surgical devices.
Bill's career in ophthalmology began in the 1970s. As president of Cavitron Surgical Systems, he worked with Dr. Charles Kelman in developing and marketing the world's first phacoemulsifier system. While highly controversial in the 1970s, phacoemulsification gradually became the preferred cataract removal technique in the early 1980s. For many years, Cavitron led the cataract instrumentation market.
CooperVision purchased Cavitron in the early 1980s, and Bill joined the company as president of the surgical division. CooperVision expanded its product line to include a wide variety of cataract surgical products-IOLs, viscoelastic solutions, disposable devices, lasers, and custom packs-and became the market leader in many product categories.
In 1989, Alcon acquired CooperVision in an effort to build a strong presence in cataract surgical devices. Bill joined Alcon as general manager of the Irvine Technology Center, where a number of the company's cataract devices, including the Legacy 20000 phacoemulsifier and a broad line of disposable items, were designed and manufactured.
Bill remained with Alcon until 1995. He then joined Mentor Ophthalmics as president of the ophthalmology division. At Mentor, he was responsible for the company's ophthalmic products including IOLs, cautery devices, and surgical instruments.